Upperton Pharma Constructs New GMP Manufacturing Plant
The 50,000 square-foot facility will feature 10 new manufacturing sites with commercial capabilities.
Upperton Pharma Solutions, a contract development and manufacturing organization (CDMO), has completed construction of its new $19.6 million, good manufacturing practice (GMP) manufacturing headquarters in Nottingham, UK.
Located less than two miles from Upperton’s current HQ, the 50,000 square feet facility houses 10 new GMP manufacturing suites, quality control laboratories, and formulation development with pilot plant capabilities.
The new site provides Upperton with a manufacturing footprint increase from 1,300 to 13,000 square feet, and an expansion of analytical laboratory space, from 880 to 8,500 square feet. It has the capability to handle highly potent and controlled drugs in a range of dosage forms and support early formulation development, clinical trial supplies from Phase 1 to Phase 3, and niche-scale commercial manufacture. The facility has been designed to increase Upperton’s operational footprint, enabling the CDMO to support more customer projects and meet larger-scale requirements.
The facility has benefited from a significant investment in commercial scale equipment, offering powder blending up to 250 kg per batch, capsule filling up to 40,000 capsules/hour, dry granulation processing up to 10 kg/hour, and tablet pressing up to 120,000 tablets/hour. The goal is to become fully operational by Q4 of 2023 for development and non-GMP manufacturing, with a view to starting GMP operations in January 2024.
“We are delighted with the progress of our Nottingham facility since we first began on this journey in January 2023,” says Nikki Whitfield, Upperton CEO. “This build completion is a significant milestone for us and represents our significant growth as a company.”
